Absence of Persistent Magnetic Oscillations in Type-II Superconductors

We report on a numerical study intended to examine the possibility that magnetic oscillations persist in type II superconductors beyond the point where the pairing self-energy exceeds the normal state Landau level separation. Our work is based on the self-consistent numerical solution for model superconductors of the Bogoliubov-deGennes equations for the vortex lattice state. In the regime where the pairing self-energy is smaller than the cyclotron energy, magnetic oscillations resulting from Landau level quantization are suppressed by the broadening of quasiparticle Landau levels due to the non-uniform order parameter of the vortex lattice state, and by splittings of the quasiparticle bands. Plausible arguments that the latter effect can lead to a sign change of the fundamental harmonic of the magnetic oscillations when the pairing self-energy is comparable to the cyclotron energy are shown to be flawed. Our calculations indicate that magnetic oscillations are strongly suppressed once the pairing self-energy exceeds the Landau level separation.Comment: 7 pages, revtex, 7 postscript figure

TIC 378898110: A bright, short-period AM CVn binary in TESS

AM CVn-type systems are ultracompact, helium-accreting binary systems which are evolutionarily linked to the progenitors of thermonuclear supernovae and are expected to be strong Galactic sources of gravitational waves detectable to upcoming space-based interferometers. AM CVn binaries with orbital periods ≲ 20–23 min exist in a constant high state with a permanently ionised accretion disc. We present the discovery of TIC 378898110, a bright (G = 14.3 mag), nearby (309.3 ± 1.8 pc), high-state AM CVn binary discovered in TESS two-minute-cadence photometry. At optical wavelengths this is the third-brightest AM CVn binary known. The photometry of the system shows a 23.07172(6) min periodicity, which is likely to be the ‘superhump’ period and implies an orbital period in the range 22–23 min. There is no detectable spectroscopic variability. The system underwent an unusual, year-long brightening event during which the dominant photometric period changed to a shorter period (constrained to 20.5 ± 2.0 min), which we suggest may be evidence for the onset of disc-edge eclipses. The estimated mass transfer rate, log(M˙ /M⊙yr−1 ) = −6.8±1.0, is unusually high and may suggest a high-mass or thermally inflated donor. The binary is detected as an X-ray source, with a flux of 9.2+4.2 −1.8 ×10−13 erg cm−2s−1 in the 0.3–10 keV range. TIC 378898110 is the shortest-period binary system discovered with TESS, and its large predicted gravitational-wave amplitude makes it a compelling verification binary for future space-based gravitational wave detectors

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Whole-genome sequencing reveals host factors underlying critical COVID-19

Critical COVID-19 is caused by immune-mediated inflammatory lung injury. Host genetic variation influences the development of illness requiring critical care1 or hospitalization2,3,4 after infection with SARS-CoV-2. The GenOMICC (Genetics of Mortality in Critical Care) study enables the comparison of genomes from individuals who are critically ill with those of population controls to find underlying disease mechanisms. Here we use whole-genome sequencing in 7,491 critically ill individuals compared with 48,400 controls to discover and replicate 23 independent variants that significantly predispose to critical COVID-19. We identify 16 new independent associations, including variants within genes that are involved in interferon signalling (IL10RB and PLSCR1), leucocyte differentiation (BCL11A) and blood-type antigen secretor status (FUT2). Using transcriptome-wide association and colocalization to infer the effect of gene expression on disease severity, we find evidence that implicates multiple genes—including reduced expression of a membrane flippase (ATP11A), and increased expression of a mucin (MUC1)—in critical disease. Mendelian randomization provides evidence in support of causal roles for myeloid cell adhesion molecules (SELE, ICAM5 and CD209) and the coagulation factor F8, all of which are potentially druggable targets. Our results are broadly consistent with a multi-component model of COVID-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication; or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between cases of critical illness and population controls is highly efficient for the detection of therapeutically relevant mechanisms of disease

Intraregional 87Sr/86Sr variation in Nubia: New insights from the Third Cataract

Previous research of 87Sr/86Sr variability in human dental tissue from the Nile Valley has shown diversity in bioavailable strontium across the landscape. Local ranges, determined from faunal sampling, have been suggested for several sites in Nubia, including Tombos (Third Cataract, Sudan). This study builds on previous research by testing human and faunal dental enamel samples from three sites in the Third Cataract region: Tombos, Hannek, and Abu Fatima. The addition of Abu Fatima and Hannek into the assessment of the Third Cataract region brings new temporal and socioeconomic juxtapositions that can shed light on migration and locality in Bronze Age Nubia.Two faunal samples, a sheep from Abu Fatima and a horse from Tombos, had 87Sr/86Sr values that were consistent with the previously established local Third Cataract strontium range. Seven of the 29 human samples tested for Abu Fatima are suggestive of non-local origin and consistent with the Second Cataract region. One of the four individuals tested from Hannek may have migrated to the region from Egypt or the Second Cataract region. Lastly, four of the 30 samples from Tombos indicate possible non-local origin; the 87Sr/86Sr values may suggest Egypt, the Second Cataract, or the Fourth Cataract as places of origin. These findings suggest complex human migration networks were present in the Nile Valley during the Bronze Age. We support the continued examination of migration using strontium while acknowledging that further research needs to be done.Bioarchaeolog